MX9602577A - Tratamiento de arterioesclerosis y xantoma. - Google Patents

Tratamiento de arterioesclerosis y xantoma.

Info

Publication number
MX9602577A
MX9602577A MX9602577A MX9602577A MX9602577A MX 9602577 A MX9602577 A MX 9602577A MX 9602577 A MX9602577 A MX 9602577A MX 9602577 A MX9602577 A MX 9602577A MX 9602577 A MX9602577 A MX 9602577A
Authority
MX
Mexico
Prior art keywords
arteriosclerosis
preventives
therapeutic agents
treatment
troglitazone
Prior art date
Application number
MX9602577A
Other languages
English (en)
Other versions
MXPA96002577A (es
Inventor
Yoshio Tsujita
Hiroyoshi Horikoshi
Masashi Shiomi
Takashi Ito
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Priority to MX9602577A priority Critical patent/MX9602577A/es
Publication of MXPA96002577A publication Critical patent/MXPA96002577A/es
Publication of MX9602577A publication Critical patent/MX9602577A/es

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una combinacion de uno o más inhibidores de HMG-CoA reductasa (por ejemplo pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin o atorvastatin) con uno o más sensibilizadores de insulina (por ejemplo troglitazona, pioglitazona, englitazona, BRL-49653, 5-(4-{2-[1-(4-2'-piridilfenil)etilidenoaminooxi]et oxi}benciltiazolidino-2,4-diona,5-{4-(5-metoxi-3-m etilimidazo[5,4-b]-piridin-2-ilme-toxi)bencil}tiaz olidino-2,4-diona o su clorhidrato, 5-[4-(6-metoxi-1-metilbencimidazol-2-ilmetoxi)benc il]tiazolidino-2,4-diona, 5-[4-(1-meti]benzimidazol-2-ilmetoxi)-bencil]tiazo lidino-2,4-diona y 5-[4-(5-hidroxi-1,4-6,7-tetrametil-bencimidazol-2- ilmetoxi)bencil]tiazolidino-2,4-diona) exhibe un efecto sinergístico y es significativamente mejor en la prevencion y/o tratamiento de arterioesclerosis y/o xantoma que cualquiera de los componentes de la combinacion por sí solo.
MX9602577A 1996-07-02 1996-07-02 Tratamiento de arterioesclerosis y xantoma. MX9602577A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX9602577A MX9602577A (es) 1996-07-02 1996-07-02 Tratamiento de arterioesclerosis y xantoma.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP167291/1995 1995-07-03
MX9602577A MX9602577A (es) 1996-07-02 1996-07-02 Tratamiento de arterioesclerosis y xantoma.

Publications (2)

Publication Number Publication Date
MXPA96002577A MXPA96002577A (es) 1998-01-01
MX9602577A true MX9602577A (es) 1998-01-31

Family

ID=39164797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9602577A MX9602577A (es) 1996-07-02 1996-07-02 Tratamiento de arterioesclerosis y xantoma.

Country Status (1)

Country Link
MX (1) MX9602577A (es)

Similar Documents

Publication Publication Date Title
PT1479385E (pt) Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
AU3006992A (en) Stabilized Pharmeceutical Compositions of HMG-CoA Reductase Inhibitors
IL108007A0 (en) Treatment of inflammatory bowel disease with ifn-gamma inhibitors
IL141785A0 (en) A pharmaceutical composition containing an ap2 inhibitor
NZ514478A (en) A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
BG105800A (en) Benzoheterocycles and their use as mek inhibitors
MXPA01006472A (es) Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
HUP0202853A2 (hu) A retigabin alkalmazása neuropátiás fájdalom kezelésére
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
TW225534B (es)
ZA943744B (en) Therapeutic substituted guanidines
ZA925946B (en) Tetrahydroindazole tetrahydrocyclopentapyrazole and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors
IL110943A0 (en) Compositions for the treatment of skin disorders
GB9804886D0 (en) Therapeutic combination
AU2002308337A1 (en) Compounds and methods for inhibiting axillary malodour
BG105953A (en) Method for treating copd
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
MX9602577A (es) Tratamiento de arterioesclerosis y xantoma.
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
RS20050420A (en) Prevention and treatment of alzheimer's disease
HUT75529A (en) Use of dimeticone for treating constipation
EP0528515A3 (en) Hmg-coa reductase inhibitors in the prevention of restenosis following coronary angioplasty
HK1024872A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
IT1255470B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees